Not a good buy right now for an impatient investor: momentum is slightly bearish (MACD histogram negative and expanding) and there is no Intellectia buy signal today.
Near-term upside exists (options positioning is strongly call-skewed and insiders have been buying aggressively), but price is sitting on/just below the pivot and can easily retest support first.
Better “buy now” setup would require either (1) a clean bounce confirmation off S1 ~$12.91 or (2) a breakout/reclaim above R1 ~$14.19; at the current $13.54 the edge is not strong enough to call it a buy.
Technical Analysis
Trend/Momentum: MACD histogram at -0.122 and negatively expanding → bearish momentum building, not a fresh reversal signal.
RSI: RSI(6) ~46.4 (neutral) → not oversold; no “snap-back” signal.
Moving averages: converging → consolidation/indecision rather than a clear uptrend.
Key levels: Pivot ~13.55 (price ~13.54 sitting at pivot). Resistance: 14.19 then 14.59. Support: 12.91 then 12.51.
Pattern-based odds (provided): modest positive bias (next day/week) but small magnitude; not strong enough to override the weak MACD.
Activity: Today’s option volume (59) is 39% of the 30D average (muted), but open interest is elevated vs avg (131.6%) → positioning is there, but today isn’t a major “new flow” day.
Volatility: IV30 32% vs historical vol ~48% with low IV percentile (12.75) → options are relatively cheap vs realized; market not pricing big near-term moves.
Technical Summary
Sell
0
Buy
13
Positive Catalysts
→ incremental support/less downside fear.
Neutral/Negative Catalysts
Technicals are not aligned for an immediate entry: MACD bearish and expanding while price is stalling at the pivot.
Earnings tone mixed: Q4 GAAP EPS $0.65 missed by $0.04 (per news), which can cap near-term multiple expansion.
Revenue prints are mixed in the provided data (news cites Q4 revenue down ~2.7% YoY, while the financial snapshot shows Q4 revenue up ~11.6% YoY) → uncertainty around the clean growth trajectory.
Broader tape weak today (S&P 500 -1.17%), which can pressure smaller financial names intraday.
EPS: $0.65, -5.80% YoY (and also noted as a slight miss vs expectations in the news).
Takeaway: topline and net income growth are positive, but per-share earnings are slipping YoY, suggesting profitability/structure headwinds despite revenue growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes are mildly constructive but not bullish: both firms kept neutral-ish stances (Market Perform / Neutral) while raising price targets.
Keefe Bruyette (2026-01-30): PT raised to $14 from $13; Market Perform maintained.
Piper Sandler (2026-01-09): PT raised to $13 from $12.50; Neutral maintained; cited 2026 EPS guidance midpoint ($2.35) above prior Street view, but noted stock underperformed after Investor Day.
Wall Street pros/cons view: Pros—guidance appears supportive and targets edged higher; Cons—ratings remain neutral and recent post-event price action suggests skepticism about near-term upside.
Wall Street analysts forecast NEWT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEWT is 14.5 USD with a low forecast of 12.5 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NEWT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEWT is 14.5 USD with a low forecast of 12.5 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 13.550
Low
12.5
Averages
14.5
High
18
Current: 13.550
Low
12.5
Averages
14.5
High
18
Keefe Bruyette
NULL -> Market Perform
maintain
$13 -> $14
AI Analysis
2026-01-30
Reason
Keefe Bruyette
Price Target
$13 -> $14
AI Analysis
2026-01-30
maintain
NULL -> Market Perform
Reason
Keefe Bruyette raised the firm's price target on NewtekOne to $14 from $13 and keeps a Market Perform rating on the shares.
Piper Sandler
Neutral
maintain
$13
2026-01-09
Reason
Piper Sandler
Price Target
$13
2026-01-09
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on NewtekOne to $13 from $12.50 and keeps a Neutral rating on the shares as the stock underperformed as much as 6% following the company's Investor Day. While the firm was somewhat surprised by the stock reaction, Piper believes the primary driver was the 2026 EPS guidance midpoint of $2.35, which was above the Street estimate of $2.21 going into the investor day.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEWT
